BioSymetrics and Moleculera Partner to Advance Personalized Treatment for Immune-mediated Neuropsychiatric Disorders | Prolog Ventures

BioSymetrics and Moleculera Partner to Advance Personalized Treatment for Immune-mediated Neuropsychiatric Disorders

October 1, 2024

Moleculera Labs announces rebrand to Moleculera Biosciences as company expands into new sectors

July 30, 2024 on Moleculera

Moleculera Forms Collaboration with Quest Diagnostics to Broaden Access to its Neuropsychiatric Autoantibody Testing

January 17, 2024 on Moleculera

Moleculera Labs Awarded $500,000 Grant Funding to Develop Predictive Treatment Algorithm

January 11, 2024 on Moleculera

Moleculera and General Genomics to Provide Personalized Medicine for Neuropsychiatric Disorders

July 26, 2022 on Moleculera